GSK1795091 + GSK3359609

GSK1795091 + GSK3359609 is an investigational combination therapy comprising two immuno-oncology agents developed by GSK for the treatment of advanced solid tumors and other cancers. **GSK1795091** is a potent and selective synthetic glycolipid agonist of toll-like receptor 4 (TLR4), designed to activate innate immunity by stimulating monocytes, macrophages, and dendritic cells, leading to cytokine production and antigen presentation. **GSK3359609** (also known as feladilimab) is a monoclonal antibody acting as an agonist for the inducible T-cell costimulator (ICOS), a receptor expressed on activated T cells, to enhance T cell activation, proliferation, and anti-tumor immune response. The combination is intended to simultaneously activate both innate and adaptive immunity in the tumor microenvironment, with the goal of producing synergistic or additive anti-tumor effects[1][2][4][7][10].